126 related articles for article (PubMed ID: 37070920)
1. Botulinum toxin infusion into the mesenteric artery has selective action on peristalsis in a rat model: experimental research.
Borrello A; Agnes A; Panunzi S; Piergentili I; Rossetto O; Fabris F; Magalini S; Gui D
Eur Rev Med Pharmacol Sci; 2023 Apr; 27(7):3171-3180. PubMed ID: 37070920
[TBL] [Abstract][Full Text] [Related]
2. Evidence for central antispastic effect of botulinum toxin type A.
Matak I
Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons.
Matak I; Rossetto O; Lacković Z
Pain; 2014 Aug; 155(8):1516-1526. PubMed ID: 24793910
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.
Lawrence GW; Ovsepian SV; Wang J; Aoki KR; Dolly JO
Neuropharmacology; 2013 Jul; 70():287-95. PubMed ID: 23485402
[TBL] [Abstract][Full Text] [Related]
5. Beyond neuromuscular activity: botulinum toxin type A exerts direct central action on spinal control of movement.
Šoštarić P; Matić M; Nemanić D; Lučev Vasić Ž; Cifrek M; Pirazzini M; Matak I
Eur J Pharmacol; 2024 Jan; 962():176242. PubMed ID: 38048980
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis.
Nemanić D; Mustapić M; Matak I; Bach-Rojecky L
Eur J Pharmacol; 2024 Jan; 963():176279. PubMed ID: 38123005
[TBL] [Abstract][Full Text] [Related]
7. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Caleo M; Spinelli M; Colosimo F; Matak I; Rossetto O; Lackovic Z; Restani L
J Neurosci; 2018 Nov; 38(48):10329-10337. PubMed ID: 30315128
[TBL] [Abstract][Full Text] [Related]
8. Lasting Peripheral and Central Effects of Botulinum Toxin Type A on Experimental Muscle Hypertonia in Rats.
Šoštarić P; Vukić B; Tomašić L; Matak I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232926
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
10. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Shen J; Ma J; Lee C; Smith BP; Smith TL; Tan KH; Koman LA
J Orthop Res; 2006 May; 24(5):1128-35. PubMed ID: 16602109
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins a and B into the amygdala in rats.
Gasior M; Tang R; Rogawski MA
J Pharmacol Exp Ther; 2013 Sep; 346(3):528-34. PubMed ID: 23772062
[TBL] [Abstract][Full Text] [Related]
12. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
13. Onset dynamics of type A botulinum neurotoxin-induced paralysis.
Lebeda FJ; Adler M; Erickson K; Chushak Y
J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):251-67. PubMed ID: 18551355
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
Adler M; Capacio B; Deshpande SS
Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Effects of Botulinum Toxin Doses on Nerve Regeneration in Rats with Experimentally Induced Sciatic Nerve Injury.
Hwang S; Seo M; Lee TH; Lee HJ; Park JW; Kwon BS; Nam K
Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133195
[TBL] [Abstract][Full Text] [Related]
17. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.
Jurasinski CV; Lieth E; Dang Do AN; Schengrund CL
Toxicon; 2001 Sep; 39(9):1309-15. PubMed ID: 11384718
[TBL] [Abstract][Full Text] [Related]
18. Pre- and Post-synaptic Effects of Botulinum Toxin A on Submandibular Glands.
Xu H; Shan XF; Cong X; Yang NY; Wu LL; Yu GY; Zhang Y; Cai ZG
J Dent Res; 2015 Oct; 94(10):1454-62. PubMed ID: 26078423
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection.
Cai BB; Francis J; Brin MF; Broide RS
Neuroscience; 2017 Jun; 352():155-169. PubMed ID: 28389376
[TBL] [Abstract][Full Text] [Related]
20. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
